Thymalin vs Thymulin: The Immune Peptide Evidence Compared (2026)

Thymalin and thymulin sound almost identical, and both come from the thymus, the small gland behind your breastbone that trains your immune system. But they are not the same thing, and the gap in the evidence behind each one is wider than most sellers admit. This review lays out what each peptide actually is, what the studies show, where the data is strong, and where it is thin enough to see through.

What the Thymus Does and Why These Peptides Exist

The thymus is where T-cells learn their job. T-cells are the white blood cells that hunt infected cells, coordinate the rest of the immune system, and keep the body from attacking itself. In your teens the thymus is large and busy. After that it slowly shrinks and fills with fat, a process called thymic involution. By your 50s and 60s, far fewer new T-cells get made.

Why does this matter? Because the slow loss of T-cell production is one of the main reasons older people catch more infections, recover slower, and respond worse to vaccines. Scientists call the broad decline of the aging immune system immunosenescence. The thymus is at the center of it. If you could nudge the thymus to keep working, the thinking goes, you might blunt some of that decline. That hope is exactly what sells thymic peptides.

Researchers have spent decades trying to bottle the signals the thymus uses to mature T-cells. Thymalin and thymulin are two of those attempts, born in different countries and decades. They share a goal: restore some of the immune signaling that fades with age. They differ in almost everything else, from chemical makeup to the kind of evidence behind them.

A quick word on naming, because the two are easy to mix up. Thymalin ends in "-alin" and is a Russian extract. Thymulin ends in "-ulin" and is a French single molecule. They are also cousins to thymosin alpha-1 and thymosin beta-4, which are different peptides again. Marketing copy often blurs these together as if any "thymic peptide" does the same thing. They do not.

Thymalin: A Peptide Mixture From Calf Thymus

Thymalin is not a single molecule. It is an extract made from the thymus glands of young calves, containing a mix of short peptides. It was developed in the Soviet Union in the 1970s and is still used as a registered drug in Russia and a few neighboring countries. It is given by injection, usually into muscle.

Because it is a mixture, "thymalin" describes a preparation, not one defined compound. Russian researchers, led most prominently by Vladimir Khavinson, identify several very short active peptides inside it, often written as KE, EW, and EDP. The proposed mechanism is unusual: these tiny peptides are said to enter the cell nucleus and bind directly to specific DNA sequences or to histone proteins, the spools DNA wraps around. By doing so, they are thought to switch certain genes on or off, including genes that drive T-cell production and immune protein synthesis.

That mechanism is interesting but should be read with caution. Much of the work supporting it comes from a single research school, and the gene-binding model is not as broadly confirmed as, say, a hormone binding a well-mapped surface receptor.

What the Thymalin Evidence Shows

The most useful recent human data on thymalin comes from a COVID-19 trial run during the pandemic. In a prospective, randomized, single-blind controlled study in older hospitalized COVID-19 patients, 36 patients received thymalin (10 mg intramuscularly daily for 10 days) on top of standard care, and 44 received standard care plus placebo. The reported results were notable:

Hospital mortality was 19.4% in the thymalin group versus 40.9% in controls (p=0.039) — roughly half.
Clinical improvement reached 80.5% with thymalin versus 59% in controls (p=0.039).
Lymphocyte recovery happened faster (about 7.4 days versus 10.8 days; p=0.002), and T-cells, B-cells, and NK cells all rose roughly two-fold.
Inflammatory markers C-reactive protein and IL-6 dropped more sharply with thymalin.

Honest reading: this is a real randomized trial with a meaningful outcome (death), which is rare for peptides like this. But it was small (80 patients), single-blind rather than double-blind, run at one site, and not independently replicated. One trial, however striking, is a starting point, not proof.

The other widely cited thymalin data is even older and weaker by modern standards. Khavinson and colleagues reported that thymalin, alone or combined with the pineal peptide epithalamin, reduced mortality in elderly patients over a 6-8 year observation, with combined annual treatment linked to a roughly two-fold or greater drop in death rates. Those numbers get repeated everywhere in peptide marketing. The catch is that this work was open-label, conducted by the developers, and never reproduced by independent groups outside that research network. Extraordinary longevity claims need extraordinary, replicated evidence. This does not clear that bar.

Here is the trap people fall into. When you see "reduced mortality two-fold" you picture a modern drug trial with thousands of patients, independent monitors, and a placebo nobody could tell apart from the real thing. That is not what this was. Open-label means everyone knew who got the peptide. Developer-run means the people with the most to gain designed and judged the study. Neither fact makes the result fake. Both make it weak. The honest position is to treat the longevity numbers as a hypothesis worth testing, not a finding you can bank on.

How Thymalin Is Studied and Dosed

In the trials that exist, thymalin is reconstituted from a powder with sterile saline and injected into muscle. The COVID-19 study used 10 mg once daily for 10 days. Russian clinical practice has historically used short courses of a few milligrams over one to two weeks, sometimes repeated seasonally. There is no agreed-upon "anti-aging" dose backed by real outcome data, despite what sellers post. Anyone quoting a precise long-term protocol for healthy people is going past the evidence. If you want to understand the general mechanics of preparing injectable peptides, see our peptide reconstitution guide — though that is about how it is done, not an endorsement of doing it.

Thymulin: A Single Zinc-Dependent Nonapeptide

Thymulin is a precisely defined molecule. It is a nonapeptide — a chain of exactly nine amino acids (Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn). It was discovered in the late 1970s by the French immunologist Jean-François Bach, who first isolated it from blood serum and named it facteur thymique sérique (FTS), or serum thymic factor. The name thymulin came later, once the zinc connection was understood.

That zinc connection is the most important fact about thymulin. The peptide is biologically dead without a zinc ion bound to it. Zinc locks the peptide into the correct three-dimensional shape so it can fit its receptor. The interaction between zinc and thymulin is so tight that researchers describe thymulin as a true metallopeptide, and the active form is often written FTS-Zn. Without zinc, the peptide circulates but the immune system cannot read the signal.

This matters for aging. As reviews of the thymus-neuroendocrine axis describe, blood thymulin activity falls with age. Part of that fall is the shrinking thymus making less peptide, and part is age-related zinc deficiency leaving the peptide inactive. Studies on neuroendocrine-thymus plasticity highlight zinc and arginine as levers that can partly restore thymulin activity, which is why some research pairs thymulin with zinc rather than studying it alone.

What the Thymulin Evidence Shows

Thymulin's mechanism is well characterized. It binds high-affinity receptors on immature T-cells (thymocytes) and pushes them through maturation, inducing the surface markers CD2, CD3, CD4, and CD8 that define functional T-cells. It also supports natural killer cell activity and can dampen inflammatory signaling. A thorough review of thymulin's physiology and therapeutic potential lays out this biology in detail and is the best single source for the molecule.

But here is the honest problem: most of thymulin's promising therapeutic data is from animals, not people. A 2019 study found that thymulin reduced inflammatory pain in rats with adjuvant-induced inflammation, cutting thermal hyperalgesia, paw swelling, spinal microglia activation, and the cytokines TNF-alpha and IL-6. That is a clean mechanistic result. It is also a rat study, and rat results often fail to carry over to humans.

Human clinical data on thymulin is sparse and dated. One of the few examples is a small open trial of thymulin (FTS-Zn) in rheumatoid arthritis patients from 1987, which followed clinical and immune changes but was uncontrolled and tiny. There is no modern, large, randomized human trial establishing thymulin as a treatment for any condition.

It is worth being clear about why so much thymulin research stalled. By the time its biology was well mapped in the 1980s and 1990s, the field of immunology had shifted toward recombinant proteins like interferons and monoclonal antibodies, which could be made pure and patented cleanly. A naturally occurring nonapeptide that depends on zinc was harder to turn into a blockbuster drug. So the science is solid, but the clinical development largely stopped. That is a different problem from "the science says it doesn't work" — it is closer to "nobody finished testing it in people."

The Zinc Angle Is the Practical Takeaway

If there is one usable idea in the thymulin literature, it is not "inject thymulin." It is "fix your zinc." Because thymulin cannot function without zinc, and because zinc deficiency is genuinely common in older adults, restoring normal zinc status can raise the activity of the thymulin you already make. Researchers studying neuroendocrine-thymus plasticity lean hard on this point. Correcting a real zinc deficiency is cheap, well understood, and something a doctor can actually test for and treat. That is a far better-supported move than buying a research-grade peptide of unknown purity.

Head-to-Head: How They Compare

Feature	Thymalin	Thymulin
What it is	Mixture of short peptides extracted from calf thymus	Single defined nonapeptide (9 amino acids)
Discovered	1970s, Soviet Union (Khavinson group)	Late 1970s, France (Bach; FTS / serum thymic factor)
Defined structure	No — a preparation, not one molecule	Yes — exact sequence known
Zinc dependent	Not specifically	Yes — inactive without zinc (FTS-Zn)
Proposed mechanism	Short peptides bind DNA/histones, alter gene expression	Binds T-cell receptors, drives thymocyte maturation
Best human evidence	Randomized COVID-19 trial (n=80) showing lower mortality	Old, small, uncontrolled trials (e.g., 1987 RA study)
Strongest data type	One randomized human trial; rest open-label	Mechanistic and animal studies
Regulatory status (US)	Not FDA approved	Not FDA approved
Biggest weakness	Single research school; longevity claims unreplicated	Almost no modern human trials

The cleanest way to summarize: thymulin has the better-understood molecule and mechanism, while thymalin has the more impressive (but unreplicated and single-source) human outcome data. Neither has the kind of large, independent, double-blind human trials that would let a doctor confidently prescribe it for immune aging.

Evidence Grading

Being blunt about the strength of evidence:

Thymalin for severe COVID-19 in older adults: low-to-moderate. One genuine randomized trial with a hard endpoint, but small, single-blind, single-site, unreplicated.
Thymalin for longevity or general anti-aging: very low. Open-label, developer-run, never independently reproduced.
Thymulin mechanism and T-cell biology: moderate-to-strong as basic science.
Thymulin as a human therapy for any condition: very low. Mostly animal and old uncontrolled data.

What Would Actually Change the Picture

It is fair to ask what it would take to move either peptide from "interesting" to "proven." The answer is the same as for any drug:

A large, multi-site, double-blind, placebo-controlled trial — ideally several, run by groups with no financial stake in the result.
Hard outcomes people care about, like fewer infections, fewer hospitalizations, or better vaccine response, not just lab numbers that shift on paper.
Independent replication. The thymalin COVID-19 result is the single most promising data point in this whole area. If another team reran it and got the same mortality drop, that would matter enormously. Until then, it sits as one trial.

Neither peptide has this yet. That is the plain truth that most sales pages skip.

How They Relate to Other Thymic Peptides

Both peptides sit in a family that includes thymosin alpha-1, the best-studied thymic peptide and the only one approved as a drug in many countries (often for hepatitis and as an immune adjuvant). If your interest is immune support with the most human data behind it, thymosin alpha-1 is the more evidence-backed cousin — see our thymosin alpha-1 research review for that comparison. Thymalin is frequently studied or marketed alongside the pineal peptide epithalon, which targets aging through a different pathway; our epithalon pineal research review covers that one.

If you are weighing any of these against established therapy, it is worth understanding the general side effects and risks of peptide therapy first.

Alternatives With More Evidence

If your real goal is a stronger immune system as you age, the boring options have far better evidence than either peptide:

Approach	Evidence strength	Notes
Staying current on vaccines (flu, COVID, shingles, pneumococcal)	Strong	Largest, most consistent protection for older adults
Correcting zinc deficiency (if tested and confirmed)	Moderate	Directly relevant to thymulin biology; cheap and testable
Vitamin D repletion if deficient	Moderate	Modest effect on respiratory infection risk
Sleep, exercise, not smoking	Strong (indirect)	Well-documented immune and mortality benefits
Thymosin alpha-1	Moderate (approved abroad)	Most clinically tested thymic peptide
Thymalin / thymulin	Low to very low	Promising signals, no modern confirmatory trials

None of this is exciting. All of it is better supported than injecting a research-grade thymic peptide bought online.

Safety: What Is and Is Not Known

For both peptides, the honest answer is that long-term human safety data is limited.

Thymalin has the longer track record of human use, since it has been a registered drug in Russia for decades and was dosed in the COVID-19 trial without reports of serious adverse events in that small group. Still, "used for decades in one country" is not the same as a modern safety database. Because it is an animal-derived extract, batch-to-batch consistency and contamination are real concerns, especially with products bought online.

Thymulin's safety in humans is essentially uncharacterized by modern standards. It has been given in old small trials and extensively in animals, but there is no large human safety dataset.

General cautions that apply to both:

Neither is FDA approved. Products sold to consumers in the US are typically labeled "for research use only," which means no agency is checking purity, dose, or sterility.
Stimulating or modulating the immune system carries theoretical risk for people with autoimmune disease, those on immune-suppressing drugs, organ transplant recipients, and anyone with an active cancer.
Injectable products bought from unregulated vendors carry infection and contamination risk on top of the unknowns about the peptide itself.

Sourcing matters more here than with almost any other category, because there is no regulatory floor. If you are researching vendors, our guide to peptide vendor quality standards explains what third-party testing should actually cover.

Who Each One Is For

Realistically, neither thymalin nor thymulin is a consumer health product with proven benefits. The accurate framing is who finds them interesting and why.

Thymalin draws interest from people focused on immune aging and from those persuaded by the COVID-19 mortality data. The strongest signal — fewer deaths in sick older patients — is exactly the kind of result that justifies more trials. It does not justify self-treating a healthy person for "longevity."

Thymulin draws interest from people who care about understanding mechanisms, especially the zinc connection. Anyone genuinely interested in thymulin's biology should pay attention to their zinc status first, since zinc deficiency alone shuts the peptide down regardless of how much is present.

For most people, the right move is not to source either peptide but to talk to a physician about evidence-based ways to support immune function and to treat the kind of immune problem they actually have.

Frequently Asked Questions

Are thymalin and thymulin the same peptide?

No. Thymalin is a mixture of short peptides extracted from calf thymus glands. Thymulin is a single, precisely defined nine-amino-acid molecule discovered separately in France. They share a thymic origin and a goal of supporting T-cell function, but they are different substances with different chemistry, mechanisms, and evidence.

Which one has stronger human evidence?

It depends on what you mean by stronger. Thymalin has one genuine randomized human trial showing lower mortality in older COVID-19 patients, which is more than thymulin can claim. But thymalin's other big claims, especially around longevity, come from a single research group and have never been independently replicated. Thymulin has better-understood basic biology but almost no modern human trial data. Neither meets the bar for confident medical use.

Why does zinc matter so much for thymulin?

Thymulin is biologically inactive without a zinc ion bound to it. The zinc holds the peptide in the exact shape it needs to fit its receptor on T-cells. This is why the active form is written FTS-Zn and why age-related zinc deficiency, not just thymus shrinkage, lowers thymulin activity as people get older.

Are these peptides FDA approved?

No. Neither thymalin nor thymulin is approved by the FDA for any use in the United States. Thymalin is a registered drug in Russia and some neighboring countries. In the US both are generally sold only as research chemicals, which means purity, dosing, and sterility are not verified by any regulator.

Is it safe to inject thymalin or thymulin?

There is no good answer because the long-term human safety data does not exist for either. Thymalin has decades of clinical use in Russia and was tolerated in a small COVID-19 trial, but that is not a modern safety database. Immune-modulating peptides carry theoretical risks for people with autoimmune conditions, cancer, or transplants, and unregulated injectables add contamination and infection risk. This is a conversation to have with a physician.

This article is for informational purposes only and is not medical advice. Talk to a qualified healthcare provider before starting any peptide, supplement, or therapy, especially one that affects your immune system.